Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -45

Novo Nordisk shares tumble after company warns of sales hit this year

AI-generated analysis

📉 Novo Nordisk shares fell as much as 14% after the company lowered guidance, forecasting a 5% to 13% decline in sales and operating profit for 2026.

💊 The outlook is heavily impacted by significant pricing pressure in the U.S. market and the loss of drug exclusivity in China, Brazil, and Canada.

🚀 CEO Mike Doustdar highlighted strong early adoption of the new oral Wegovy pill as a key driver for future volume growth in the United States.

⚔️ The company is fighting to regain footing against fierce competition from rival Eli Lilly, whose tirzepatide has surpassed Novo in U.S. market share.

📊 Fourth-quarter net sales reached 79.1 billion Danish kroner ($12.5 billion), slightly beating estimates, with Wegovy sales growing 17% to 21.9 billion kroner.

🏥 Ozempic revenue remained flat at constant exchange rates in Q4, bringing in 31.8 billion kroner compared to the prior year period.

🌍 Novo plans to roll out Wegovy in additional markets and introduce a higher 7.2 mg dose in several countries during 2026.

💰 The company is banking on its next-generation injectable CagriSema to help revive its stock price and market position.

🤝 Novo and Eli Lilly agreed to cut prices for their best-selling GLP-1 drugs under a deal with the Trump administration, expected to increase volumes but reduce total sales revenue.

📉 Analysts note that while guidance cuts may trigger further downgrades, investors might view the oral Wegovy launch as a clearing event to buy into the company's potential volume inflection.

Bullish Signals
  • Novo Nordisk reported fourth-quarter net sales of 79.1 billion Danish kroner ($12.5 billion), slightly exceeding analyst estimates of 77.8 billion kroner.
  • Wegovy sales grew 17% in the fourth quarter to reach 21.9 billion kroner, demonstrating strong momentum for the company's flagship weight-loss drug.
  • The company has successfully launched an oral version of Wegovy in the U.S., creating a new revenue stream and competitive advantage against injectable-only rivals.
  • CEO Mike Doustdar expressed confidence in the promising early uptake of the oral pill, which could help close the gap with rival Eli Lilly in the direct-to-patient channel.
  • Novo plans to expand Wegovy availability to more markets and introduce a higher 7.2 mg dose in several countries during 2026 to drive volume growth.
Risk Factors
  • The company forecasts a sales and operating profit decline of 5% to 13% for 2026, driven by lower prices in the U.S. and loss of exclusivity abroad.
  • Novo faces intense competition from Eli Lilly's tirzepatide, which has surpassed Novo in U.S. market share due to more pronounced weight loss effects.
  • Ozempic revenue remained flat at constant exchange rates in Q4, indicating stagnation in the company's original blockbuster drug.
  • The loss of exclusivity for Semaglutide in Canada, Brazil, and China in 2026 will expose Novo's portfolio to generic competition in these key markets.
Full Analysis
Novo Nordisk shares plummeted as much as 14% after the Danish pharmaceutical giant warned that sales and operating profit growth will decline between 5% and 13% in 2026. The outlook reflects significant headwinds, primarily driven by lower pricing in its largest market, the United States, and the loss of exclusivity for its blockbuster drugs, Wegovy and Ozempic, in key international markets including China, Brazil, and Canada. CEO Mike Doustdar acknowledged the challenging environment but expressed confidence in the promising early uptake of the newly launched oral version of Wegovy in the U.S. The company aims to recapture market share against rival Eli Lilly by leveraging this new oral treatment and its next-generation injectable, CagriSema, while expanding availability of Wegovy in more countries. Financially, Novo reported fourth-quarter net sales of 79.1 billion Danish kroner ($12.5 billion), slightly beating analyst estimates, though operating profit was down 14% year-on-year. Ozempic revenue remained relatively flat at constant exchange rates, while Wegovy sales grew 17%. The company faces a strategic battle to maximize its lead in the direct-to-patient channel before rival tirzepatide products fully capture market share.